{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:11:12Z","timestamp":1790287872405,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ctrv.2025.102944","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T13:54:38Z","timestamp":1745157278000},"page":"102944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Adjuvant CDK4\/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty"],"prefix":"10.1016","volume":"136","author":[{"given":"Saroj","family":"Niraula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2025.102944_b0005","first-page":"116","article-title":"The Effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMAOncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102944_b0010","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.102944_b0015","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ctrv.2025.102944_b0020","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102944_b0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-020-05755-7","article-title":"Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+\/HER2- advanced breast cancer (PALOMA-1, TRIO-18)","volume":"183","author":"Finn","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102944_b0030","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102944_b0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.ctrv.2025.102944_b0040","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2025.102944_b0045","first-page":"00121","article-title":"Final Survival Results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+\/HER2- breast cancer and residual disease after neoadjuvant chemotherapy - PENELOPE-B","volume":"S0923\u20137534","author":"Loibl","year":"2025","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102944_b0050","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: The PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102944_b0055","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102944_b0060","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102944_b0065","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.24.00886","volume":"42","author":"Freedman","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102944_b0070","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-020-16559-0","article-title":"Quantifying CDK inhibitor selectivity in live cells","volume":"11","author":"Wells","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.102944_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693104","article-title":"Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast cancer","volume":"11","author":"George","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102944_b0080","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1038\/s41598-024-53151-8","article-title":"Comparative overall survival of CDK4\/6 inhibitors in combination with endocrine therapy in advanced breast cancer","volume":"14","author":"Kappel","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102944_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"issue":"346","key":"10.1016\/j.ctrv.2025.102944_b0090","doi-asserted-by":"crossref","first-page":"e8668","DOI":"10.1136\/bmj.e8668","article-title":"Differential dropout and bias in randomised controlled trials: when it matters and when it may not","volume":"21","author":"Bell","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2025.102944_b0095","doi-asserted-by":"crossref","unstructured":"Haslam A, Ranganathan S, Prasad V, Olivier T. CDK4\/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. Eur J Cancer Oxf Engl 1990. 2024 Aug;207:114192.","DOI":"10.1016\/j.ejca.2024.114192"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102944_b0100","first-page":"679","article-title":"Biased evaluation in cancer drug trials-how use of progression-free survival as the primary end point can mislead","volume":"8","author":"Tannock","year":"2022","journal-title":"JAMAOncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102944_b0105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-020-0368-0","article-title":"Informative censoring - a neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2025.102944_b0110","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","article-title":"NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2025.102944_b0115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/JCO.2020.38.15_suppl.505","article-title":"Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial)","volume":"38","author":"Khan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102944_b0120","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent Cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+\/HER2- breast cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102944_b0125","article-title":"Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer","volume":"199","author":"Tolaney","year":"2024","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102944_b0130","article-title":"Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials","volume":"3","author":"Sherry","year":"2024","journal-title":"BMJ Oncol"},{"issue":"32","key":"10.1016\/j.ctrv.2025.102944_b0135","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1200\/JCO.23.01423","article-title":"Progression-free survival should not be used as a primary end point for registration of anticancer drugs","volume":"41","author":"Booth","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2025.102944_b0140","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102944_b0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102944_b0150","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102944_b0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T10:28:51Z","timestamp":1746095331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":31,"alternative-id":["S0305737225000660"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102944","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant CDK4\/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102944"}}